The BEAM Alliance is a network of 72 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices, including in vitro diagnostics.
“We are pleased to welcome grit42 who joins the BEAM Alliance as an Associated Member and are looking forward to see how their technology could help to unlock loads of currently unused data in the AMR space!” said Florence Séjourné, President of the BEAM Alliance.
CEO and co-founder of grit42, Claus Stie Kallesøe, continues, “We’re thrilled to join the BEAM Alliance – the premier European network within the AMR community. As we’re already part of multiple AMR-related projects, including being deeply involved in IMI’s (Innovative Medicines Initiative) AMR Accelerator, we see this as a natural step towards expanding our platform to further support the global fight against antimicrobial resistance.”
About the BEAM Alliance and AMR
Antimicrobial Resistance has now gained the spotlight from governments worldwide as an urgent threat. Back in 2016 the Davos Declaration also clearly demonstrated the commitment of the pharmaceutical industry to combating the challenge of AMR with signatures by over 100 companies and organizations. The BEAM Alliance was a key influencer in this declaration and, since then, has multiplied actions in outlaying the challenges associated with combating AMR from an industry perspective.
Developing new solutions to combat AMR is hampered by market failure as the corresponding products have costly R&D with low return on investment. A new paradigm to incentivize and encourage new products in the space is urgently needed and accompanying policies must embrace the vision of all the key players in the AMR sphere, particularly SMEs. Indeed, SMEs are collectively developing a broad portfolio of preventive, diagnostic and therapeutic products but are struggling to survive owing to the significant lack of investment in the field.
The BEAM Alliance is advocating for SME-compatible policies that are flexible enough to incorporate the vast variety of tools needed to tackle AMR.